Please try another search
For the three months ended 31 March 2021, GWPharmaceuticals PLC- ADR revenues increased 26% to $152.5M.Net loss increased from $8M to $19.7M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Sales, general and administra increase of 41% to$88.4M (expense), Research and development expe increase of30% to $56.4M (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 152.47 | 148.22 | 137.05 | 121.3 |
Gross Profit | 140.66 | 137.8 | 129.42 | 112.59 |
Operating Income | -21.03 | -22.81 | -12.72 | -9.04 |
Net Income | -19.68 | -29.15 | -12.19 | -8.83 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 934.34 | 939.51 | 910.26 | 870.58 |
Total Liabilities | 197.97 | 198.42 | 175.81 | 153.64 |
Total Equity | 736.37 | 741.09 | 734.45 | 716.94 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -11.72 | -27.39 | -33.31 | -34.34 |
Cash From Investing Activities | -10.82 | -28.01 | -23.03 | -19.22 |
Cash From Financing Activities | -5.61 | -1.13 | -0.9 | -1.65 |
Net Change in Cash | -28.65 | -50.18 | -56.6 | -59.38 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review